Skip to content

AEROBIC EXERCISES FOR SICKLE CELL DISEASE CHILDREN AND ADOLESCENTS WITH EARLY STAGE AVASCULAR NECROSIS OF FEMORAL HEAD

EFFICACY OF MILD-MODERATE AEROBIC EXERCISES ON PAIN, PHYSICAL FUNCTION AND QUALITY OF LIFE OF SICKLE CELL DISEASE CHILDREN AND ADOLESCENTS WITH EARLY STAGE AVASCULAR NECROSIS OF FEMORAL HEAD

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR202202915078002
Enrollment
66
Registered
2022-02-01
Start date
2022-03-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Haematological Disorders Paediatrics

Interventions

Mild to moderate aerobic exercise group
Conventional care

Sponsors

Adeyinka Olanrewaju
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Participants with early stage (Ficat I-III) avascular necrosis of femoral head (Ficat, 1985) who have been diagnosed to have sickle cell disease. The Ficat staging is the most widely used for classification of AVNFH. 2. Children and adolescents who are aged 9 – 18 years.

Exclusion criteria

Exclusion criteria: 1. Participants with a history of severe motor disability (Alvarado, Ward, Muntz, Thompson, Rodeghier, Fernhall et al, 2015) that will have major impact on daily activities (e.g. stroke, musculoskeletal problems). 2. Participants with a concurrent condition other than sickle cell disease that predisposed them to the development of avascular necrosis of the femoral head (e.g., a history of chronic systemic steroid use or alcoholism). 3. Participants that have had crises for at least 1 month and blood transfusion three months prior to intervention (Dedeken et al, 2014). This is to prevent vasooclussive crises. 4. Participants who are not ambulant since some of the activities involve walking. 5. Participants without hip pain. 6. Patients on hydroxyurea: Hydroxyurea is a drug that reduces the frequency of painful episodes in SCD patients. It raises the level of Fetal Heamoglobin (HbF) and the haemoglobin level to about 50%.

Design outcomes

Primary

MeasureTime frame
Pain

Secondary

MeasureTime frame
Range of motion, functional capacity, activities of daily, contractures, muscle power and quality of life,

Countries

Nigeria

Contacts

Public ContactUmaru Badaru

Senior Lecturer Department of Physiotherapy Bayero University Kano

umbadaru.pth@buk.edu.ng+2348035913759

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026